Role of Nutritional Care and General Guidance for Patients with Advanced or Metastatic Gastric Cancer

Mizukami, Takuro; Piao, Yongzhe

doi:10.2217/fon-2021-0186

Cited by 21 publications

(25 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Apatinib is a novel small molecule tyrosine kinase inhibitor of the vascular endothelial growth factor receptor (VEGFR-2) that competitively binds to the receptor intracellular tyrosine F6 site and highly selectively inhibits VEGFR-2 enzymatic activity, thus blocking the signal transduction pathway after VEGFR binding to VEGFR-2 and inhibiting tumor vascular production [ 8 ]. A clinical study has shown that the basic control rate of apatinib for advanced gastric cancer can reach 42% [ 9 ]. It can respond to the normal function of mitochondria in tumor cells and induce apoptosis and differentiation of tumor cells.…”

Section: Discussionmentioning

confidence: 99%

“…Serum tumor markers serve to determine tumor severity and prognosis, and common serum tumor markers include carcinoembryonic antigen (CEA), glycoantigen 199 (CA199), and glycoantigen 125 (CA125) [ 8 ]. Clinical research has shown that Th1 and Th2-like cytokines regulate immune function, and trauma may lead to immune imbalance due to abnormal Th1 and Th2-like cytokines levels [ 9 ]. Accordingly, the present study recruited 100 patients with advanced gastric cancer between October 2019 and December 2020 to assess the efficacy of apatinib plus S-1 therapy in the treatment of advanced gastric cancer patients and the effect on the levels of tumor markers, Th1 and Th2-like cytokines.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of Apatinib plus S-1 Therapy in the Treatment of Advanced Gastric Cancer Patients and the Effect on the Levels of Tumor Markers and Th1 and Th2-Like Cytokines

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. To assess the efficacy of apatinib plus S-1 therapy in the treatment of advanced gastric cancer patients and the effect on the levels of tumor markers and Th1 and Th2-like cytokines. Methods. From October 2019 to December 2020, 100 patients with advanced gastric cancer assessed for eligibility were recruited and assigned at a ratio of 1 : 1 to receive either S-1 regimen (tegafur, gimeracil, and oteracil potassium capsules) (observation group) or apatinib plus S-1 therapy (experimental group). Outcome measures included clinical efficacy serum tumor marker levels, Th1 and Th2-like cytokine levels, time to progression (TTP), overall survival (OS), and adverse events. Results. The S-1 therapy plus apatinib was associated with a significantly higher efficacy versus S-1 therapy alone ( P < 0.05). The eligible patients given S-1 therapy plus apatinib showed significantly lower levels of serum carcinoembryonic antigen (CEA), glycoantigen 199 (CA199), and glycoantigen 125 (CA125) versus those receiving S-1 therapy ( P < 0.05). S-1 therapy plus apatinib outperformed the single therapy of S-1 therapy in mitigating the levels of interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), interleukin-4 (IL-4), and interleukin-10 (IL-10) ( P < 0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups ( P > 0.05). S-1 therapy plus apatinib was associated with a significantly shorter TTP (5.2 ± 0.7 months) and a longer OS (9.3 ± 2.5 months) versus S-1 therapy alone (7.1 ± 1.3, 5.1 ± 1.3 months) ( P < 0.05). Conclusion. The efficacy of apatinib plus S-1 therapy showed better improvement in lowering the serum tumor marker levels and ameliorating the Th1 and Th2-like cytokine levels versus S-1 therapy alone, so it is worthy of clinical application.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Efficacy of Apatinib plus S-1 Therapy in the Treatment of Advanced Gastric Cancer Patients and the Effect on the Levels of Tumor Markers and Th1 and Th2-Like Cytokines

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…In general, malnutrition in patients with gastrointestinal tumors was correlated with shorter survival time, poorer tolerance to chemotherapy, and worse quality of life ( 4 – 6 ). If malnutrition, especially undernutrition, has not been identified and corrected in time, it could lead to reduced immune function, increased infectious complications, prolonged hospitalization, increased mortality rates of patients, and more associated medical expenditure ( 7 – 9 ). Therefore, it is of great significance to make an accurate assessment of the nutritional status in time, and then draw up an individualized plan for the nutritional treatment, thereby improving or even reversing the clinical outcomes of patients with gastrointestinal tumors ( 10 ).…”

Section: Introductionmentioning

confidence: 99%

Comparison of the Suitability Between NRS2002 and MUST as the First-Step Screening Tool for GLIM Criteria in Hospitalized Patients With GIST

et al. 2022

View full text Add to dashboard Cite

ObjectiveThe Global Leader Initiative on Malnutrition (GLIM) criteria have been recommended for malnutrition diagnosis recently, for which the first step is malnutrition risk screening with any validated tool. This study aims to investigate the incidence of malnutrition risk in gastrointestinal stromal tumor (GIST) inpatients and compare the suitability of Nutritional Risk Screening 2002 (NRS2002) and Malnutrition Universal Screening Tool (MUST) as the first-step screening tool for GLIM criteria.MethodsWe retrospectively analyzed the clinical data of GIST inpatients in our hospital from January 2015 to December 2019. NRS2002 and MUST were used to screen malnutrition risk at the time of admission. The diagnostic consistency of these two tools with GLIM criteria for malnutrition was analyzed, and the predictive performance of both tools for the length of hospital stay and the occurrence of complications was also evaluated in surgical and non-surgical inpatients.ResultsA total of 269 GIST inpatients were included in this study, of which 45.7 and 40.9% were at malnutrition risk determined by NRS2002 and MUST, respectively. In non-surgical inpatients, NRS2002 and MUST had similar diagnostic consistency with GLIM criteria in sensitivity (93.0 vs. 97.7%), specificity (81.1 vs. 81.1%), and Kappa value (K = 0.75 vs. 0.80), and high nutritional risk classified by NRS2002 and malnutrition identified by GLIM criteria were found to be associated with the length of hospital stay. In surgical inpatients, MUST had better diagnostic consistency with GLIM criteria in sensitivity (86.1 vs. 53.5%) and Kappa value (K = 0.61 vs. 0.30) than NRS2002, but no factors were found associated with the length of postoperative hospital stay or the occurrence of complications.ConclusionThe malnutrition risk is common in GIST inpatients. NRS2002 is more suitable than MUST for the first-step risk screening of the GLIM scheme in non-surgical inpatients, considering its better performance in screening malnutrition risk and predicting clinical outcomes. MUST was found to have good diagnostic consistency with GLIM criteria for malnutrition in both non-surgical and surgical GIST inpatients, and further studies need to be conducted to investigate its predictive performance on clinical outcomes.

show abstract

“…In addition, elderly patients are more prone to suffer from malnutrition, sarcopenia, and weakness due to weakened body functions, organ decline, and reduced immunity ( 24 ). GC is a highly aggressive form of cancer, especially in the advanced or metastatic stage, and the symptoms of reduced nutritional intake and absorption and gastrointestinal obstruction were more obvious than in other cancer patients ( 23 , 25 ). Considering that the clinical baselines of malnourished patients were worse than those of well-nourished patients, and the associated adverse outcomes were unsurprising and obvious, consistent with the findings in this study.…”

Section: Discussionmentioning

confidence: 99%

Correlation Between Components of Malnutrition Diagnosed by Global Leadership Initiative on Malnutrition Criteria and the Clinical Outcomes in Gastric Cancer Patients: A Propensity Score Matching Analysis

Mei

Cai

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveMalnutrition is recognized as a risk factor for poor outcome in patients with gastric cancer (GC). In 2018, the Global Leadership Initiative on Malnutrition (GLIM) published standardized criteria for the diagnosis of malnutrition. Our aim was to investigate whether any of the components of the GLIM diagnostic criteria were related to worse clinical outcomes in patients with GC.MethodsThis study analyzed patients with GC who underwent radical gastrectomy in our hospital between 2014 and 2019. A preoperative nutritional assessment was performed for each patient. Matching was based on the presence of three GLIM components: high weight loss (WL), low body mass index (BMI), and low skeletal muscle index (SMI).ResultsThe analysis included 1,188 patients, including 241 (20.3%) with high WL, 156 (13.1%) with low BMI, and 355 (29.9%) with low SMI. Before matching, patients who met the GLIM component criteria were mostly associated with older age, low nutritional reserves, and late tumor progression. After matching, the clinical characteristics of the three cohorts were balanced. In the matched queue, the survival prognosis of the high WL group was worse than that of the non-WL group, and the postoperative complication rate was higher in the low SMI group than in the normal SMI group (P <0.05). In addition, the clinical outcomes in the low and normal BMI groups were similar (P >0.05).ConclusionOf the GLIM criteria, high WL and low SMI may be associated with poor clinical outcomes in patients with GC, while a low BMI may not be associated with outcome.

show abstract

Role of Nutritional Care and General Guidance for Patients with Advanced or Metastatic Gastric Cancer

Cited by 21 publications

References 50 publications

Efficacy of Apatinib plus S-1 Therapy in the Treatment of Advanced Gastric Cancer Patients and the Effect on the Levels of Tumor Markers and Th1 and Th2-Like Cytokines

Efficacy of Apatinib plus S-1 Therapy in the Treatment of Advanced Gastric Cancer Patients and the Effect on the Levels of Tumor Markers and Th1 and Th2-Like Cytokines

Comparison of the Suitability Between NRS2002 and MUST as the First-Step Screening Tool for GLIM Criteria in Hospitalized Patients With GIST

Correlation Between Components of Malnutrition Diagnosed by Global Leadership Initiative on Malnutrition Criteria and the Clinical Outcomes in Gastric Cancer Patients: A Propensity Score Matching Analysis

Contact Info

Product

Resources

About